Trecondi

Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and
non-malignant diseases, and in paediatric patients older than one month with malignant diseases.

It is available in the following presentation:                  

Trecondi 1 g powder for solution for infusion:
One vial contains 1 g of treosulfan

Trecondi 5 g powder for solution for infusion:
One vial contains 5 g of treosulfan.

Trecondi is distributed in Ireland by Fannin Ltd in partnership with Medac (This link will take you to a non-Fannin Ltd. website.  Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties.) 

For a copy of the SPC please click here.

Method of Sale: POM

PA Numbers: 

EU/1/18/1351/001 (1 g, 1 vial)
EU/1/18/1351/002 (1 g, 5 vials)
EU/1/18/1351/003 (5 g, 1 vial)
EU/1/18/1351/004 (5 g, 5 vials)

 

MAH Holder: medac, Gesellschaft für klinische Spezialpräparate mbH, Theaterstr. 622880 Wedel, Germany

For any further information please speak to your local Fannin Representative or contact our medical information department for a copy of the SPC at medical@dccvital.com or via phone on 01 2907000

Additional information available on request.

Date of preparation: April 2020

IE2020/010/00

ORDER ENQUIRES:

ROI orders / enquiries please contact

+353 1 2907000

+353 1 2907111